GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nutriband Inc (NAS:NTRB) » Definitions » Quality Rank

Nutriband (Nutriband) Quality Rank


View and export this data going back to 2017. Start your Free Trial

What is Nutriband Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Nutriband Quality Rank Related Terms

Thank you for viewing the detailed overview of Nutriband's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Nutriband (Nutriband) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nutriband Inc (NAS:NTRB) » Definitions » Quality Rank
Comparable Companies
LSTA TFFP COCP NRBO CNTX QSAM FRES AXLA KALA SYBX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
9WV:Germany
Address
121 South Orange Avenue, Suite 1500, Orlando, FL, USA, 32801
Website
https://www.nutriband.com
Nutriband Inc is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
Executives
Michael Davidov director 60 EAST 42 STREET, NEW YORK NY 10165
Serguei Melnik director, 10 percent owner, officer: Chief Financial Officer
Gareth Sheridan director, 10 percent owner, officer: CEO 6064 CENTRAL COLLEGE RD., NEW ALBANY OH 43054
Vitalie Botgros director, 10 percent owner, officer: Chairman of the BOD GREGERSTR 36B, FISHAMEND C4 2401